All In Biotech

Drug Trial Radar · NCT05608837

Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema

Efficacy and Safety of Dexamethasone ophthaLmic Suspension Eye drOps in Uveitic and Post Surgical mAculaR eDema (The LEOPARD Study)

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

28

Actual

Start

May 26, 2023

Primary completion

Oct 2026

Study completion Oct 2026

Sponsor

Lead sponsor
Quan Dong NguyenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Global Ophthalmic Research Center (GORC); Oculis
First posted
Nov 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of the LEOPARD clinical trial is to investigate a new kind of steroid eye drops, OCS-01. Macular edema is a condition in which there is collection of fluid (edema) in the back of the eye (Macula) and it can lead to severe loss of vision. Among other causes, macular edema can happen because of a disease of the eye called Uveitis, and also after eye surgery. Treatment of macular edema remains a challenge as the condition may persist for several months and may lead to irreversible changes in the eye and poor vision. In the LEOPARD study the investigators wish to see how safe is the study drug (OCS-01) and how well it works, in resolving the fluid collection in the eye in patients with Uveitis or in patients who have had eye surgery. Participants will undergo detailed eye exam, and record their eye and medical history to see what their disease status is and if they can be included in the study based on the study criteria. If included, they will take the study drug OCS-01 in different doses for 24 weeks. During the study period, they will have regular eye exams to ensure their safety and to assess the usefulness of the study drug.

Conditions

  • Uveitis Related Cystoid Macular Edema
  • Cystoid Macular Edema, Postoperative

Interventions

  • OCS-01Drug

    One drop of OCS-01 eye drops, 3-6 times daily. Dosing frequency will depend on the phase of the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Central Subfield ThicknessTime frame: Baseline to 12 weeks
  2. Visual AcuityTime frame: Baseline to 12 weeks

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Retina Vitreous Associates Medical Group

    Beverly Hills, California

  • Retina Associates of Southern California

    Huntington Beach, California

  • Stein Eye Institute at UCLA

    Los Angeles, California

  • Byers Eye Institute at Stanford

    Palo Alto, California

  • Massachusetts Eye Research and Surgery Institution

    Boston, Massachusetts

  • Erie Retina Research

    Erie, Pennsylvania

  • Valley Retina Institute P.A

    McAllen, Texas

  • Texas Retina Associates

    Plano, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.